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Purpose: To evaluate the effectiveness of low-dose aspirin for the treatment of central serous 
chorioretinopathy (CSCR).
Patients and methods: Patients with classical or multifocal CSCR were treated with aspirin 
100 mg per day orally for 1 month followed by 100 mg on alternate days for 5 months. Treated 
patients were compared with historic controls consisting of patients with classical or multifocal 
CSCR previously followed up at our institution.
Results: Mean visual acuity in the group treated with aspirin started to improve after the first 
week of therapy and continued to improve throughout the following 3 months. Visual recovery 
was slower in the untreated control group than in the treated group and achieved better visual 
acuity between the first and third month from the onset of the disease. There were no adverse 
events related to the administration of aspirin.
Conclusion: The results indicate that treatment with low-dose aspirin may result in more rapid 
visual rehabilitation with fewer recurrences in patient with CSCR compared with untreated 
historic controls. The effectiveness of treatment with aspirin supports our hypothesis regarding 
the role of impaired fibrinolysis and increased platelet aggregation in the choriocapillaris in 
the pathogenesis of CSCR.
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Introduction
Central serous chorioretinopathy (CSCR) is characterized by serous detachment of 
the neurosensory retina due to focal leakage of choroidal interstitial fluid because 
of a breakdown of the retinal pigment epithelium (RPE). The neurosensory detach-
ment is sometimes associated with a detachment of the RPE. A multifocal variant of 
CSCR is also recognized. This form is characterized by multiple points of leakage on 
  fluorescein angiography (FA) secondary to widespread decompensation of the RPE 
and by a chronic course with a less favorable prognosis than classic CSCR.
While the clinical appearance of CSCR is well recognized, less is known about 
the underlying pathogenetic mechanism of the disease. Dysfunction of the RPE, 
hyperpermeability of the choroid, and choroidal ischemia have been suggested 
as the   possible primary injury responsible for the disruption of the RPE barrier 
and consequent   neurosensory detachment. Nevertheless, many reports indicate 
a focal occlusion of the choriocapillary as a cause of the decompensation of the 
overlying RPE.1–6
CSCR is reported to be associated with uncontrolled hypertension and pre-
  eclampsia, and is described in patients undergoing hemodialysis. It is classically Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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described as affecting middle-aged people, with a male 
prevalence, and in personality types who exhibit a high stress 
response.7–11
An enhanced response to stress with increased secretion 
of catecholamines and relative hypercortisolism secondary 
to hypothalamus-pituitary-adrenal axis stimulation has been 
reported in patients with CSCR.12–15 In addition, bone   marrow 
and solid organ transplantation,16,17 vasculitis,18 lupus,19 
inflammatory bowel disease,20,21 and Cushing’s syndrome22 
have also been associated with CSCR, as well as exposure 
to exogenous glucocorticoids.23,24
All the factors associated with CSCR have as their 
common denominator increased hypercoagulability and 
increased platelet aggregation. Steroids can also induce 
hypercoagulability and increased platelet aggregation. 
Increased coagulation and platelet aggregation appear to 
explain the connection between use of steroids and onset of 
CSCR through a focal, transitory, or permanent occlusion 
of the choroidal vasculature. This chain of events appears to 
be linked to an increase in plasminogen activator inhibitor 1 
(PAI-1). A previous study suggested the use of ibuprofen in 
the treatment of central serous chorioretinopathy,25 and others 
have found elevated PAI-1 in patients with CSCR.26,27 Aspirin 
possesses antiaggregant effects and is effective in reducing 
serum levels of PAI-1.
Given the evidence of a role for PAI-1 in the pathophysi-
ology of CSCR, we have started to treat patients with CSCR 
using low-dose aspirin. Our previously reported pilot study 
has shown that administration of aspirin does appear to influ-
ence the course of CSCR.28 To define the effectiveness of this 
new treatment strategy, we performed a study comparing the 
results obtained in patients treated with aspirin with those 
in a historic control group consisting of patients with CSCR 
who were not taking low-dose aspirin.
Material and methods
We enrolled all patients with active classic or multifocal 
CSCR referred between January 2005 and February 2009 
to the Retina Service of the Department of Ophthalmology, 
Hospital C Cantù, Abbiategrasso, Milan. Exclusion criteria 
were other ocular or retinal disease, history of coagulation 
abnormalities or bleeding diathesis, previous laser retinal 
photocoagulation, history of ulcerative gastric disease, preg-
nancy, or allergy to aspirin. Previous medical treatment for 
CSCR, stopped at least 15 days before enrollment, was not 
an exclusion criterion.
A complete ophthalmic examination was undertaken at 
admission in all patients, using FA and optical coherence 
tomography (OCT). FA and OCT were also performed at 
1 week, 1 month, 3 and 6 months, and 1 and 2 years. Best 
correct visual acuity (BCVA, Snellen and logMar) was 
determined at every follow-up visit.
All patients were prescribed aspirin 100 mg once daily 
for the first month and on alternate days for the following 
5 months. A full informed consent was obtained from each 
patient participating in the study. The study was approved by 
the ethics committee of our institution in conformity with 
the Declaration of Helsinki.
The prospective case series undergoing treatment 
(Group A), was compared with an historic control group 
consisting of patients with either classic or multifocal CSCR 
identified from the files of the Retina Service from June 2001 
to December 2004 (Group B) who fulfilled the same inclusion 
and exclusion criteria as Group A. Patients in Group B had 
had complete ocular examinations, including FA and OCT, 
at the same intervals as Group A. Primary endpoints were 
BCVA and number of recurrences. Secondary endpoints were 
variation in leakage points observed on FA and the course 
of serous detachment on OCT.
The Student’s t-test was used to compare BCVA values 
between groups (P value # 0.05 was accepted as statistically 
significant).
Results
Demographic data for the patient and control groups are 
shown in Table 1. Groups A and B were comparable for demo-
graphics and disease characteristics. Mean follow-up was 
18.44 ± 9.32 months for Group A and 18.93 ± 8.48 months 
for Group B (P = 0.702). BCVA is illustrated in Table 2 and 
Figure 1. As shown in Table 2, Group B had a better mean 
BCVA at the initial visit than Group A (20/31 ± 20/26 ver-
sus 20/39 ± 20/29, P , 0.0001), although in the same range 
(Group A 20/25–20/100 and Group B 20/25–20/100). After 
1 week, the difference in BCVA between the groups was still 
evident and statistically   significant (Group A 20/36 ± 20/31, 
Group B 20/32 ± 20/26, P = 0.0048). This reflects an improve-
Table 1 Demographic data
Group A Group B P value
Patients (eyes) 109 (113) 89 (95)
Bilateral disease  4 6
Multifocal central serous  
chorioretinopathy
7 unilateral 
2 bilateral
1 unilateral 
5 bilateral
Age 42.19 ± 8.34 41.90 ± 6.92 0.793
gender (M:F) 87:22 75:14
Follow-up  18.44 ± 9.32 18.93 ± 8.48 0.702Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Figure 1 Trend of mean visual acuity during follow-up.
Table 2 Mean visual acuity at the initial visit and during follow-up
Mean visual acuity (Snellen and LogMar)
Time of follow-up Group A (range) Group B (range) P value
initial visit +0.29 ± 0.16 (+0.1/+0.7) 
20/39 ± 20/29 (20/25–20/100)
+0.19 ± 0.12 (+0.1/+0.7) 
20/31 ± 20/26 (20/25–20/100)
,0.0001
One week +0.25 ± 0.19 (+0.0/+0.7) 
20/36 ± 20/31 (20/20–20/100)
+0.20 ± 0.12 (+0.1/+0.8) 
20/32 ± 20/26 (20/25–20/125)
0.0048
One month +0.14 ± 0.20 (+0.0/+0.7) 
20/28 ± 20/32 (20/20–20/100)
+0.21 ± 0.11 (+0.1/+0.7) 
20/32 ± 20/26 (20/25–20/100)
0.004
Three months +0.08 ± 0.16 (+0.0/+0.6) 
20/24 ± 20/26 (20/20–20/80)
+0.13 ± 0.12 (+0.0/+0.6) 
20/27 ± 20/26 (20/20–20/80)
0.010
six months +0.10 ± 0.17 (+0.0/+0.7) 
20/25 ± 20/30 (20/20–20/100)
+0.13 ± 0.12 (+0.0/+0.7) 
20/27 ± 20/26 (20/20–20/100)
0.102
One year +0.09 ± 0.17 (+0.0/+0.6) 
20/24 ± 20/30 (20/20–20/80)
+0.16 ± 0.13 (+0.0/+0.6) 
20/26 ± 20/27 (20/20–20/80)
0.008
Two years +0.07 ± 0.13 (+0.0/+0.5) 
20/23 ± 20/27 (20/20–20/63)
+0.17 ± 0.13 (+0.0/+0.6) 
20/30 ± 20/27 (20/20–20/80)
,0.0001
ment in visual acuity in Group A and unchanged visual acuity 
in Group B.
At 1 and 3 months, both groups improved, although 
the BVCA at 1 month (Group A 20/28 ± 20/32, Group 
B 20/32 ± 20/26, P = 0.004) and 3 months (Group A 
20/24 ± Group B 20/27 ± 20/26, P = 0.010) was better in 
Group A than Group B.
Between 1 and 3 months, visual acuity also improved in 
the untreated group. However, the patients who underwent 
treatment with aspirin showed a better and faster recovery 
than controls.
Stabilization of visual acuity in Group A and further 
improvement in Group B was noted after 6 months, with 
no significant difference between the groups (Group A 
20/25 ± 20/30, Group B 20/27 ± 20/26, P = 0.102).
However, at 1 year, BCVA in Group A was better than 
in Group B (20/24 ± 20/30 and 20/26 ± 20/27, respectively, 
P = 0.008). At the end of the follow-up period, Group A 
maintained a better BVCA than Group B (20/23 ± 20/27 
versus 20/30 ± 20/27, P , 0.0001).
As shown in Table 3, 86% of Group A had no recurrences 
during follow-up; 6.5% experienced 1–3 relapses of disease 
and 7.5% showed a persistence of CSCR.
In Group B, 57% had a resolution of CSCR with no recur-
rences, 23% had 1–3 further episodes of CSCR, and 20% 
had persistence of disease. The numbers of leakage points Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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observed at FA and the course of serous detachment shown 
at OCT are illustrated in Table 4.
Discussion
Administration of aspirin enabled a more rapid recovery 
of the Snellen BCVA and a smaller percentage of recur-
rences in comparison with the control group. The number 
of recurrences in the group treated with aspirin was also 
lower in comparison with previous studies concerning the 
long follow-up term of CSCR.29–32 Patients affected with 
the multifocal form have shown a limited benefit of therapy, 
although improvement in visual acuity was found.
None of the patients manifested adverse reactions to 
aspirin. A gastrointestinal risk exists, but appears to be 
dose-dependent. Even at low dosage, an increased gastroin-
testinal risk has been found,33 but has been very low (,3%), 
consisting of bleeding ulcers. In our series this did not occur, 
probably because of the young age of our patients, their lack 
of history of ulcerative gastric disease, and the total number 
of patients included being too small to show such a rare 
complication.
Other treatment options for CSCR are reserved for 
  persistent or chronic forms. Photodynamic therapy with verte-
porfin was introduced, but its clinical use remains controver-
sial regarding the timing and the fluence of administration.34 
More recently, intravitreal bevacizumab was suggested for 
the treatment of classic or chronic CSCR. However, we found 
only small case reports in the literature with no conclusive 
clinical outcome.35,36 Lim et al recently showed no positive 
effect of bevacizumab in classic CSCR patients compared 
with a control group.37 Another pharmacologic approach for 
treatment of CSCR consists of administration of systemic 
ketoconazole to decrease endogenous cortisol synthesis, but 
this has not been associated with an improved outcome in a 
preliminary study or in a later clinical trial.38,39
Conclusion
The results of this study seem to demonstrate the effectiveness 
of lower-dose aspirin in the treatment of CSCR but, due to limi-
tations related to use of an historic group as a control, cannot 
be considered definitive. As demonstration of the self-limited 
nature of CSCR, we observed a spontaneous improvement 
of BCVA in the untreated group in the period between 1 and 
3 months. Further studies will be needed to be able to indi-
vidualize the dosage and duration of administration of aspirin 
and to define better the role of single factors in the coagulative 
cascade in the onset of this multifactorial illness.
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